Efficacy and safety of the fìxed combination Timolol 0.5%/Travoprost 0.004% compared the concomitant administration to the single components

Aim. Aim of the study was to evaluate the safety and efficacy of the once daily fixed combination timolol 0.5%/ travoprost 0.004% versus twice daily timolol 0.5% associated with once daily travoprost 0.004% in patients with primary open angle glaucoma or ocular hypertension. Metbods. A prospective study was carried out in patients with primary open angle glaucoma (IOP one eyez 18 nunHg and S30 nunHg and IOP both eyes S30 nunHg).The IOP was measured continuously at 15 days, l month, 2 months, 3 months, 4 months, 5 months and 6 months after initiation of treatment with timolol 0.5%twice a day, tirnolol 0.5%twice a day and travoprost 0.004% once daily, and timolol 0.5%/ travoprost 0.004%fixed combination once daily. Results. Eighty eyes of 40 patients, mean age 70.45±10.15 years were treated with only timo- 101 0.5%for l month obtaining a mean reduction in IOP of 9.88%.Switching to timolol 0.5%/ travoprost 0.004% resulted in adequate IOP control (11.3%). After three months of treatment with fixed combination (timolol 0.5%/ travoprost 0.004%) the IOP reduced was statistica1lysignificant. Conclusion. Timolol O.5%/travoprost 0.004% fixed combination was well-tolerated and produced significant additional IOP reduction when switched from other anti-glaucoma drugs in patients with primary open angle glaucoma or ocular hypertension. Both topical and systemic side-effects were scarce and tolerability was good.